Watch SRPT. Know when insiders buy.
One email the day a filing lands. Free.
SRPT
Sarepta Therapeutics, Inc.
18.67
+0.28 +1.52%
USD · close Sep 25
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
75
PASS · shorts 75
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $2BP/E —DIV YIELD —FCF YIELD 4.15%REV TTM $2B −20.4%NET INCOME −$136.7MNET DEBT $276.5M52W 14.86 – 24.45SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | $401.3M | −34.3% | — | $13.3M | −$4.9M | −102.5% | -0.05 | $197.1M | $555K | $196.5M | Aug 5 |
| Q1 2026 · Mar 31 | $730.8M | −1.9% | — | $358.4M | $331M | — | 2.88 | −$202.7M | $2.1M | −$204.8M | Aug 5 |
| Q4 2025 · Dec 31 | $442.9M | −32.7% | -6.6% | −$411.6M | −$412.2M | −359.2% | -3.93 | $131.2M | $3.6M | $127.6M | Mar 2 |
| Q3 2025 · Sep 30 | $399.4M | −14.5% | 54.9% | −$103.4M | −$50.6M | −250.5% | -0.50 | −$14.6M | $22.9M | −$37.5M | Mar 2 |
| Q2 2025 · Jun 30 | $611.1M | +68.4% | 59.0% | $115.6M | $196.9M | +2947.9% | 1.89 | $261.3M | $31.8M | $229.5M | Aug 5 |
| Q1 2025 · Mar 31 | $744.9M | +80.2% | 63.6% | −$300.4M | −$447.5M | −1339.0% | -4.60 | −$583.4M | $43.7M | −$627.1M | Aug 5 |
| Q4 2024 · Dec 31 | $658.4M | +65.9% | 76.8% | $161.7M | $159M | +248.4% | 1.50 | $92M | $38.1M | $54M | Mar 2 |
| Q3 2024 · Sep 30 | $467.2M | +40.8% | 72.4% | $22.2M | $33.6M | — | 0.34 | −$70.7M | $37.3M | −$108M | Mar 2 |
| Q2 2024 · Jun 30 | $362.9M | — | 87.1% | −$701K | $6.5M | — | 0.07 | $14.9M | $29.2M | −$14.2M | Mar 2 |
| Q1 2024 · Mar 31 | $413.5M | — | 74.7% | $34.9M | $36.1M | — | 0.37 | −$242.1M | $32.4M | −$274.5M | Mar 2 |
| Q4 2023 · Dec 31derived | $396.8M | — | — | $24.6M | $45.7M | — | 0.76 | −$54.7M | $19M | −$73.7M | Mar 2 |
| Q3 2023 · Sep 30 | $331.8M | — | — | −$20.8M | −$40.9M | — | -0.46 | −$114.7M | $29.7M | −$144.4M | Nov 6 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | $2.2B | 98.8% | −$699.8M | −$713.4M | -32.5% | -7.13 | −$205.5M | $102M | −$307.5M | $25M | — |
| FY2024 · to Dec 31 | $1.9B | — | $218.1M | $235.2M | 12.4% | 2.34 | −$205.8M | $137M | −$342.7M | $0 | — |
| FY2023 · to Dec 31 | $1.2B | — | −$267.8M | −$536M | -43.1% | -5.80 | −$501M | $76.1M | −$577.1M | $0 | — |
| FY2022 · to Dec 31 | $933M | — | −$536.2M | −$703.5M | -75.4% | -8.03 | −$325.3M | $30.8M | −$356.2M | — | — |
| FY2021 · to Dec 31 | $701.9M | — | −$459.7M | −$418.8M | -59.7% | -5.15 | −$443.2M | $38.5M | −$481.7M | — | — |
| FY2020 · to Dec 31 | $540.1M | — | −$564.2M | −$554.1M | -102.6% | -7.11 | $107.5M | $82.2M | $25.3M | — | — |
Every number comes from Sarepta Therapeutics, Inc.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.